Title: Vedolizumab–steroid combination therapy improves long-term prognosis in patients with
ulcerative colitis
Version: 1 Date: 28 Feb 2025
Reviewer:  Milan Lukas
Reviewer's report:
I read this article which is entitled: "Vedolizumab - steroids combination therapy improves the
prognosis in patients with ulcerativ# colitis" with great interest. There is the small (38 patients )
retrospective analysis from the two GI sites, comparing the efficacy in the induction therapy with
vedolizumab with steroids combination and vedolizumab induction therapy alone. The relusts
showed, that combo therapy was higher effective then monotherapy with vedolizumab in terms
of clinical remission and clinical response at week 2nd and week 8th.
Thjis results are fully expectable, because many years this combination in the induction therapy
in patients with ulcerative colitis is used. Despite that manuscript brought nothing news, analysis
were done very well.
I have minor  revision statement:
a) The title should be a little but changed, because the disease prognosis is usually based on the
for long term data of effectivity, but not for 8 weeks due to induction therapy.
b) In patients on the monotherapy with vedolizumab had the more severe endoscopic findings
at the baseline (MES 3) It should be comment in the discussion.
c) The most sensitive biomarker - fecal calprotectine - was not included.
Title: Vedolizumab–steroid combination therapy improves long-term prognosis in patients with
ulcerative colitis
Version: 1 Date: 28 Feb 2025
Reviewer:  Milan Lukas
Reviewer's report:
I read this article which is entitled: "Vedolizumab - steroids combination therapy improves the
prognosis in patients with ulcerativ# colitis" with great interest. There is the small (38 patients )
retrospective analysis from the two GI sites, comparing the efficacy in the induction therapy with
vedolizumab with steroids combination and vedolizumab induction therapy alone. The relusts
showed, that combo therapy was higher effective then monotherapy with vedolizumab in terms
of clinical remission and clinical response at week 2nd and week 8th.
Thjis results are fully expectable, because many years this combination in the induction therapy
in patients with ulcerative colitis is used. Despite that manuscript brought nothing news, analysis
were done very well.
I have minor  revision statement:
a) The title should be a little but changed, because the disease prognosis is usually based on the
for long term data of effectivity, but not for 8 weeks due to induction therapy.
b) In patients on the monotherapy with vedolizumab had the more severe endoscopic findings
at the baseline (MES 3) It should be comment in the discussion.
c) The most sensitive biomarker - fecal calprotectine - was not included.
Please review this paper.
user
Title: Vedolizumab–steroid combination therapy improves long-term prognosis in patients with
ulcerative colitis
Version: 1 Date: 28 Feb 2025
Reviewer:  Milan Lukas
Reviewer's report:
I read this article which is entitled: "Vedolizumab - steroids combination therapy improves the
prognosis in patients with ulcerativ# colitis" with great interest. There is the small (38 patients )
retrospective analysis from the two GI sites, comparing the efficacy in the induction therapy with
vedolizumab with steroids combination and vedolizumab induction therapy alone. The relusts
showed, that combo therapy was higher effective then monotherapy with vedolizumab in terms
of clinical remission and clinical response at week 2nd and week 8th.
Thjis results are fully expectable, because many years this combination in the induction therapy
in patients with ulcerative colitis is used. Despite that manuscript brought nothing news, analysis
were done very well.
I have minor  revision statement:
a) The title should be a little but changed, because the disease prognosis is usually based on the
for long term data of effectivity, but not for 8 weeks due to induction therapy.
b) In patients on the monotherapy with vedolizumab had the more severe endoscopic findings
at the baseline (MES 3) It should be comment in the discussion.
c) The most sensitive biomarker - fecal calprotectine - was not included.
assistant